News

Limitless X Holdings, Inc. Secures SEC Qualification for Reg A+

Limitless X Holdings, Inc. Secures SEC Qualification for Reg A+

Limitless X Holdings, Inc. Achieves SEC Qualification for Offering

Limitless X Holdings, Inc. (OTCQB: LIMX) operates with a mission to inspire individuals and enhance value for shareholders. Recently, the SEC qualified its Regulation A+ offering, marking a significant step forward for the company.

Strategic Investment Opportunity

This offering, characterized as Series D 15% Cumulative Redeemable Perpetual Preferred Stock, symbolizes a crucial turning point for Limitless X. By attaining this qualification, the company is now positioned to attract investments that will assist in strengthening its financial foundation and accelerate its growth trajectory.

Essential Offering Details

The Reg A+ offering comes with a potential size of $75 million if fully subscribed, providing a compelling opportunity for investors. A 15% annual dividend paid quarterly showcases the attractive returns for stakeholders. Each share is priced at $25.00, aimed at fostering growth across various aspects of the business.

Limitless X is adeptly channeling the proceeds from this offering toward strategic endeavors that include scaling operations, launching innovative products, and expanding its market reach to boost brand recognition.

CEO's Perspective on Investor Benefits

Jas Mathur, CEO of Limitless X, expressed excitement about this offering, emphasizing its appeal to everyday investors. With annual dividends and quarterly payouts, this initiative represents an opportunity that is often accessible primarily to institutional investors. By participating, investors gain entry into a publicly traded company that is committed to redefining the paradigms of value and innovation across industries.

Long-Term Vision of Limitless X Holdings, Inc.

Limitless X Holdings, Inc. is conceptualizing a vast and diversified ecosystem focused on pivotal sectors such as health, wellness, entertainment, and real estate. Their wholly owned subsidiary operates an impactful Direct-to-Consumer eCommerce platform that delivers products designed to optimize lifestyles and enhance overall well-being.

Future Growth Strategies

This offering presents a foundational stage for Limitless X as they push into high-growth segments. Investors are encouraged by the company's long-term vision of delivering not only financial returns but also meaningful contributions to the community and wellness sectors, enhancing both short and long-term investments.

Frequently Asked Questions

What does the SEC qualification mean for Limitless X?

The SEC qualification allows Limitless X to actively solicit investments under its Regulation A+ offering, deepening its financial resources for expansion.

What kind of stock is being offered?

Limitless X is offering Series D 15% Cumulative Redeemable Perpetual Preferred Stock, which provides a substantial dividend to shareholders.

How will the funds from the offering be used?

Funds will be allocated towards operational scaling, product development, market expansion, and brand building to enhance shareholder value.

What is the dividend rate for this offering?

The offering comes with a 15% annual dividend rate, paid out quarterly, which offers a consistent income stream for investors.

Where can I find more information about Limitless X Holdings?

For more detailed information about Limitless X Holdings, you can reach out to their media or investor relations contact listed in their announcements.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 104

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 163

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Community in Shock After Fatal Bakersfield Shooting

Updated Category News Views 98

The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 149

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 421

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 339

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 176

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 252

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 71

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading

Top 5 Most Recently Viewed Articles

Cisco's Chief Discusses Entry-Level Hiring Trends and AI

Updated Category News Views 192

Cisco's Insights on Entry-Level Hiring Trends The landscape of entry-level job opportunities is seeing a notable shift. Data from an industry student platform reveals a decrease in job postings for recent graduates. The statistics indicate a 16% year-over-year drop in entry-level positions, sparking concern among graduates and job seekers. Understanding the Current Job...

Continue Reading
FMC’s Rimisoxafen: The Game-Changer Amid Weeds' Rebellion

Updated Category News Views 248

FMC's Bold Move in the Herbicide Game Honestly, this takes me back to the dot-com era—not in tech, but in agriculture. FMC Corporation (NYSE:FMC) just pulled a doozy by getting rimisoxafen classified as a dual mode of action herbicide. This baby’s not just a gimmick; it’s a big deal for a sector that's wrestling down weeds like Palmer amaranth that’ve become a...

Continue Reading
Chord Energy Announces Earnings Call for Q2 2025 Results

Updated Category News Views 168

Chord Energy Earnings Release and Conference Call Details Chord Energy Corp. (NASDAQ: CHRD) has exciting news as it gears up to announce its financial and operational results for the second quarter of 2025. This announcement is scheduled to occur after the market closes, on an appointed date that follows the pattern of previous releases. Live Webcast and Conference Call...

Continue Reading
TuniTuni Thrives Globally with Unique Storytelling Approach

Updated Category News Views 338

TuniTuni: A Global Pioneer in Toddler Development TuniTuni is redefining early childhood physical education through its innovative approach that combines storytelling with the essential elements of physical movement. Since its inception in 2003, this leading brand has garnered attention in various regions, particularly emphasizing the importance of physical activity for...

Continue Reading
Investigation into Open Lending Holdings for Investor Losses

Updated Category News Views 363

Investigation into Open Lending Holdings for Investor Losses Faruqi & Faruqi, LLP is taking steps to look into potential claims on behalf of investors who have faced considerable losses related to Open Lending Corporation (NASDAQ: LPRO). If you have experienced financial setbacks from your investments in Open Lending, it’s important to know that you're not alone and...

Continue Reading